Literature DB >> 21506107

Tumor-induced endothelial cell apoptosis: roles of NAD(P)H oxidase-derived reactive oxygen species.

Ruei-Zeng Lin1, Tsung-Pao Wang, Ruei-Jiun Hung, Yung-Jen Chuang, Chi-Chen Michae Chien, Hwan-You Chang.   

Abstract

Many tumor cells are capable of migrating through endothelial cell (EC) junctions and disintegrating sub-endothelial extracellular matrix to achieve extravasation. We demonstrate in this study that certain solid tumor cells can induce EC apoptosis to facilitate their escape from the circulation. The EC apoptosis is triggered by elevated intracellular reactive oxygen species (ROS) levels and direct contacts with tumor cells are required. Treating ECs with antioxidants, such as ascorbate and N-acetyl-L-cysteine (NAC), and a glutathione precursor can rescue the ECs from tumor-induced apoptosis and reduce the number of tumor cells migrating across endothelial barriers. NAD(P)H oxidase was identified as the major ROS producer in the event since inhibitors and small interference RNA specific to the enzyme could abrogate the tumor-induced ROS production and hence EC death. This study also provides evidence showing that the interaction between tumor and EC increases intracellular Ca(2+) concentration and activates protein kinase C (PKC) activity, which leads to NAD(P)H oxidase activation through the serine-phosphorylation of p47(phox) subunit. These findings suggest that blocking the tumor-induced EC apoptosis is a potential way to prevent tumor metastasis.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21506107     DOI: 10.1002/jcp.22504

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

Review 1.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

2.  A microfluidic co-culture system to monitor tumor-stromal interactions on a chip.

Authors:  Nishanth V Menon; Yon Jin Chuah; Bin Cao; Mayasari Lim; Yuejun Kang
Journal:  Biomicrofluidics       Date:  2014-12-05       Impact factor: 2.800

Review 3.  Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?

Authors:  Katrien De Bock; Massimiliano Mazzone; Peter Carmeliet
Journal:  Nat Rev Clin Oncol       Date:  2011-05-31       Impact factor: 66.675

4.  Diabetes disrupts the response of retinal endothelial cells to the angiomodulator lysophosphatidic acid.

Authors:  Jorge Aranda; Ruta Motiejunaite; Eunok Im; Andrius Kazlauskas
Journal:  Diabetes       Date:  2012-03-13       Impact factor: 9.461

5.  Untargeted metabolomics reveals distinct metabolic reprogramming in endothelial cells co-cultured with CSC and non-CSC prostate cancer cell subpopulations.

Authors:  Anusha Jayaraman; Praveen Kumar; Silvia Marin; Pedro de Atauri; Francesca Mateo; Timothy M Thomson; Josep J Centelles; Stewart F Graham; Marta Cascante
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

Review 6.  [Advances in the relationship between tumor cell metabolism and tumor metastasis].

Authors:  Yalong Zhang; Nianzhen Fang; Jiacong You; Qinghua Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-11

Review 7.  Cell signaling through protein kinase C oxidation and activation.

Authors:  Daniela Cosentino-Gomes; Nathália Rocco-Machado; José Roberto Meyer-Fernandes
Journal:  Int J Mol Sci       Date:  2012-08-24       Impact factor: 6.208

8.  ATP mediates NADPH oxidase/ROS generation and COX-2/PGE2 expression in A549 cells: role of P2 receptor-dependent STAT3 activation.

Authors:  Shin-Ei Cheng; I-Ta Lee; Chih-Chung Lin; Wan-Ling Wu; Li-Der Hsiao; Chuen-Mao Yang
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

Review 9.  Markers and Biomarkers of Endothelium: When Something Is Rotten in the State.

Authors:  Nikolay V Goncharov; Alexander D Nadeev; Richard O Jenkins; Pavel V Avdonin
Journal:  Oxid Med Cell Longev       Date:  2017-11-23       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.